Evidence map›Paper›PMID 28944091›Full record

ArticleJournal of vaccines & vaccination2016

Pre-resectional Radiofrequency Ablation as a Neoadjuvant

Fumito Ito, Sharon S Evans

Open access · hybridAbstract read
In one paragraph

Article in Journal of vaccines & vaccination, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Fumito ItoCenter for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York, USA.
Sharon S EvansDepartment of Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA.
Roswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Christine B. Ambrosone · 1985 to 2026
$116.6M
LEUKOCYTE-ENDOTHELIAL CELL ADHESION IN TUMOR IMMUNITYR01CA079765 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI EVANS, SHARON S · 2000 to 2013
$3.8M
Inflammatory Control of Lymphocyte TraffickingR01AI082039 · NIAID · ROSWELL PARK CANCER INSTITUTE CORP · PI EVANS, SHARON S · 2010 to 2014
$2.3M
Adoptive Cell Therapy with Rejuvenated Antigen-Specific T CellsK08CA197966 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ITO, FUMITO · 2015 to 2019
$875k
NCI NIH HHS K08 CA197966NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA079765NIAID NIH HHS R01 AI082039
6 · The paper itself

Abstract

A lack of effective immune response against cancer is one of the major risk factors for developing local recurrence and distant metastases after curative resectional surgery. Prior studies revealed that systemic antitumor immunity is elicited by radiofrequency ablation (RFA) of tumor lesions, which is mainly considered a palliative procedure for unresectable tumors or for inoperable patients. Recently, we discovered an oncological benefit that depends on the adaptive arm of the antitumor immune response when RFA is performed in a neoadjuvant setting prior to surgical resection in preclinical murine models.

Identifiers

PMID28944091
PMCPMC5606234
OpenAlexW2341835146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.